KMT2A and acute lymphoblastic leukemia: MiR-128-3p and its validated target genes are involved in several tumorigenic molecular pathways in many cancers, such as prostate cancer, lung cancer, glioma, colorectal cancer, breast cancer, and MLL-AF4 acute lymphocytic leukemia (ALL).